Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Block-LC SGB Treatment Trial

perjantai 13. marraskuuta 2026 päivittänyt: National Institute of Allergy and Infectious Diseases (NIAID)

Block-LC: A Phase 2 Randomized, Single-blind, Sham-controlled Trial to Evaluate the Quality of Life and Symptom Severity After Stellate Ganglion Block Procedure in Persons 18-65 Years With Long COVID, Followed by a Sham-to-active Open Label Extension

This study is a randomized, single-blind, sham-controlled trial to assess the efficacy and safety of a series of two sets (four total) of bilateral Study Procedures (SGB or Sham) administered to adults with Long COVID (Figure 1) followed by a sham-to-active OLE trial. Approximately 272 (136 per arm) participants will be randomized 1:1 to receive SGB or a sham Study Procedure. Following screening and completion of baseline PROs, eligible participants will undergo in-person baseline assessments and blood draw. Those who are confirmed to be eligible will complete a pre-procedure telehealth visit and then be randomized 1:1 at Day 1 to receive either active SGB (Arm 1) or sham (Arm 2); each administration is referred to as a "Study Procedure". Participants will receive a total of four Study Procedures with follow up visits to assess recovery. Outcomes will be assessed at 28 days, 56 days, 12 weeks, and 26 weeks. Follow-up visits at weeks 12 and 26 allow for assessment of durability of response and delayed adverse events (AEs). The primary objective is to compare the change in overall HRQoL from baseline to 8 weeks between participants aged 18-65 years with Long COVID randomized to a series of two sets of bilateral SGB or sham Study Procedures.

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

This study is a randomized, single-blind, sham-controlled trial to assess the efficacy and safety of a series of two sets (four total) of bilateral Study Procedures (Stellate Ganglion Block (SGB) or Sham) administered to adults with Long COVID followed by a sham-to-active OLE trial. Approximately 272 (136 per arm) participants will be randomized 1:1 to receive SGB or a sham Study Procedure. Following screening and completion of baseline PROs, eligible participants will undergo in-person baseline assessments and blood draw. Those who are confirmed to be eligible will complete a pre-procedure telehealth visit and then be randomized 1:1 on Day 1 to receive either active SGB (Arm 1) or sham (Arm 2); each administration is referred to as a "Study Procedure". Participants will receive a total of four Study Procedures with follow up visits to assess recovery. Outcomes will be assessed at 28 days, 56 days, 12 weeks, and 26 weeks. The inclusion of follow-up visits at weeks 12 and 26 allows for assessment of durability of response and delayed adverse events (AEs). The primary objective is to compare the change in overall HRQoL from baseline to 8 weeks between participants aged 18-65 years with Long COVID randomized to a series of two sets of bilateral SGB or sham Study Procedures. The secondary objectives are 1) To compare the change in fatigue severity from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 2) To compare the change in attention and working memory from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 3) To compare the change in processing speed and executive function from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 4) To compare the change in verbal fluency from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 5) To compare the change in learning and memory from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 6) To compare the change in orthostatic intolerance symptoms from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 7) To compare the change in functional capacity from baseline to 8 weeks between participants randomized to a series of two sets of bilateral SGB or sham Study Procedures. 8) To evaluate safety in participants randomized to a series of two sets of bilateral SGB or sham Study Procedures.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

272

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

    • Oregon
      • Portland, Oregon, Yhdysvallat, 97239-3011
        • Oregon Health and Science University

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 65 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  1. Aged 18 to 65 years, inclusive, at the time of consent.

  2. History of SARS-CoV-2 infection*a-d

    1. Shown by (1) a positive nucleic acid amplification test (NAAT) or antigen test,*b OR (2) meeting clinical criteria AND an epidemiologic link to a confirmed case.*c,d
    2. See Section 8.1, Visit 00A, for a list of acceptable documentation required to confirm past SARS CoV-2 infections.
    3. Clinical criteria is defined as either (1) acute onset of fever AND cough (influenza like illness); OR (2) acute altered/loss of taste or smell + one additional symptom including fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, or anorexia; OR (3) three or more symptoms, including fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, or anorexia.
    4. Epidemiologic link is defined as having contact (within 6 feet for at least 15 minutes) with someone sick with SARS-CoV-2 test-positive COVID-19 illness.
  3. Clinical evidence of Long COVID*a and Long COVID symptoms that cannot be attributed to another cause upon investigator review of medical history and evaluation prior to study entry. *b

    1. Participants must meet the 2024 NASEM definition for Long COVID.
    2. In the judgment of the investigator.
  4. Has a substantial reduction or impairment in ability to engage in pre-illness levels of activity (occupational, educational, social, or personal life) following COVID-19 illness.*a

    a. Based on symptom-specific criteria.

  5. Presents at least two of the primary symptoms of interest*a,f that cannot be explained by an alternative diagnosis in the judgment of a site investigator.

    1. Primary symptoms of interest are fatigue,*b cognitive difficulty,*c orthostatic intolerance,*d and PEM.*e
    2. Fatigue is defined by a previous clinical diagnosis or a mean score of >/= 4 total score on the Fatigue Severity Scale.
    3. Cognitive difficulty is defined by a previous clinical diagnosis or a T-score of <40 on the PROMIS-29+2 Cognitive Function - Abilities subdomain.
    4. Orthostatic intolerance is defined by a previous clinical diagnosis or one question with a score > 2 on the Orthostatic Intolerance Questionnaire.
    5. PEM is defined by a previous clinical diagnosis or score of >/= 2 for severity and frequency for at least one applicable question on the Long COVID Symptom Screener.
    6. Symptoms must be "new" (i.e., onset during or following a COVID-19 illness) with a duration of at least 6 months and be present at the time of screening. Symptom(s) may fluctuate during trial, as long as they meet the above initial criteria.
  6. Has a PROPr score of </= 0.35 on the screening PROMIS-29+ 2.

  7. Acceptable clinical screening laboratory evaluations.*a,b INR must be <1.3 and platelets must be >100,000 per microliter. Other screening laboratory evaluations must be within normal reference ranges or Grade 1 per the DAIDS Table with no clinical significance (NCS) per investigator's discretion.*c

    1. The screening labs will include CBC, Comprehensive metabolic panel, PT,INR, and PTT. (CBC includes Hgb, WBC (with differential), Hct, and Plt. Comprehensive metabolic panel includes blood glucose, blood urea nitrogen, creatinine, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin, total protein, bicarbonate, chloride, sodium, potassium.)
    2. Additional screening labs to identify causes of fatigue unrelated to Long COVID: thyroid-stimulating hormone (TSH), free thyroxine (FT4), and vitamin B12.
    3. Clinical laboratory evaluations that are outside the site reference range, but not graded by the toxicity table, are not exclusionary unless deemed clinically significant by an investigator. Values graded by the toxicity table to be Grade 2 or higher are considered exclusionary even if they fall within the site-specific normal reference range.
  8. Fluent in English or Spanish.

  9. Willing and able to provide informed consent before initiation of any study activities.

  10. Able to understand and agree to comply with all planned study activities*a and be available for all study visits in the randomized controlled portion of the study.

    1. Participants still may enroll if they are unable or unwilling to complete blood draw(s) for biomarkers. An initial blood draw for screening clinical laboratory assessments is required to be completed prior to randomization.
  11. Agrees to maintain*a,b non-study medications, vitamins, and supplements at current doses for the duration of the randomized controlled portion of the trial.*c

    1. Except as prescribed or instructed by their treating clinician.
    2. Agree to not begin other new over-the-counter (OTC) medications, vitamins, and supplements unless prescribed or instructed by their treating clinician.
    3. OTC pain relief is allowed (e.g., ibuprofen, NSAIDs, acetaminophen) and should be documented.
  12. Agrees to maintain non-pharmacological Long COVID therapies (e.g., vagal nerve stimulation, acupuncture) consistent*a for the duration of the randomized controlled portion of the trial.

    a. Except as instructed by their treating clinician.

  13. Agrees to adhere to all lifestyle considerations in Section 5.5 for the duration of the randomized controlled portion of the trial.

  14. Agrees to utilize electronic data capture for the e-Memory Aid and electronic PROs and have access to a device connected to the internet for completion.

Exclusion Criteria:

  1. Known acute SARS-CoV-2 infection <= 30 days from the time of randomization.

  2. Has received any previous autonomic or sympathetic blocks prior to randomization or plans to receive any non-study related autonomic or sympathetic blocks during the study intervention period.

  3. Contraindications to SGB*a,b

    1. These include but are not limited to active infection at the injection site, bleeding disorders, current anticoagulation therapy, current dual antiplatelet therapy (single agent aspirin therapy is permitted), known allergies to local anesthetics, known vocal cord paralysis, clinically significant phrenic nerve dysfunction or diaphragmatic paralysis, prior pneumonectomy, or other condition that, in the judgment of the proceduralist, would increase the risk of complications from SGB, including transient recurrent laryngeal nerve or phrenic nerve blockade.
    2. Any other condition that, in the judgment of the investigator, substantially increases the procedural risk of SGB (e.g., severe cardiopulmonary disease).
  4. Known clinically significant ophthalmologic condition(s)*a a. These include but are not limited to untreated or uncontrolled glaucoma, active retinal vascular disease or retinal ischemia, acute or incompletely treated retinal detachment, or another clinically significant ophthalmologic condition that, in the investigator's judgment, could be adversely affected by changes in ocular perfusion or could interfere with assessment of the expected ocular effects of SGB.

  5. History of major surgery,*a myocardial infarction, or cerebrovascular events*b <=365 days of randomization.

    1. Major surgery refers to procedures associated with substantial physiologic stress, significant postoperative recovery, hospitalization before or following surgery, prolonged functional limitation, major fluid shifts, or blood loss, or clinically meaningful postoperative inflammatory or cardiopulmonary effects that could confound study outcomes or safety assessment. Examples include but are not limited to major thoracic, cardiac, abdominal, vascular, neurosurgical, transplant, or major orthopedic procedures (e.g., joint replacement or spine surgery). Minor outpatient procedures or minimally invasive interventions with rapid recovery and minimal systemic impact will not be considered major surgery unless deemed clinically significant by the investigator.
    2. Major cerebrovascular events include but are not limited to ischemic stroke, transient ischemic attack, intracerebral hemorrhage, subarachnoid hemorrhage, cerebral venous sinus thrombosis, carotid or vertebral artery dissection, or another clinically significant acute cerebrovascular event within 365 days before randomization. Participants with a known untreated, unsecured, or otherwise clinically significant intracranial or cervical vascular abnormality are excluded regardless of the date of diagnosis. These abnormalities include intracranial aneurysm, cerebral arteriovenous malformation, dural arteriovenous fistula, carotid or vertebral artery aneurysm or pseudoaneurysm, active arterial dissection, or another vascular abnormality that may increase the risk of SGB. Participants with definitively treated lesions may be considered eligible after documentation of stability and review by the site investigator and proceduralist.
  6. Intercurrent illness, acute systemic infection, or acute fever, or unresolved recurrent fever at the time of enrollment that would increase procedural risk or may confound the safety assessments.

  7. Planned elective surgeries during study participation.

  8. Clinical diagnosis of ME/CFS, autonomic dysfunction, or other infection-associated chronic conditions with an onset prior to the qualifying SARS-CoV-2 infection.

  9. Positive pregnancy test at Visit 00A/00B/00C or within 24 hours before SGB/Sham Study Procedure; or plans to become pregnant during the randomized controlled trial period.

  10. Breastfeeding at the time of randomization or has plans to breastfeed during the randomized controlled trial period.

  11. Is of child-bearing potential and not using a highly effective contraceptive method during the study intervention period (Visit 00A through Visit 12).

  12. Participation in another interventional clinical trial <= 30 days of randomization or planned participation during the study intervention period (Visit 00A through Visit 12).

  13. Began a new medication, supplement, or vitamin, or changed doses of a medication, supplement, or vitamin <= 30 days of randomization.

  14. Initiation/discontinuation of medications*a that could affect autonomic function, cardiovascular function, participant safety, or assessment of study outcomes </= 30 days of randomization.*b,c

    1. Examples include beta-blockers, midodrine, fludrocortisone, ivabradine, pyridostigmine, droxidopa, clonidine, guanfacine, antihypertensive agents, antiarrhythmic agents, or other autonomic- or cardiovascular-modulating therapies.
    2. Participants receiving these medications are eligible provided they have remained on a stable regimen for at least 30 days before randomization.
    3. In the investigator's judgment.
  15. Use of the following supplements garlic, hawthorn, ginkgo, turmeric or curcumin, ginger, high-dose vitamin E, nattokinase, and serrapeptase </= 30 days of randomization.

  16. Initiation </= 30 days of randomization or planned initiation during the randomized controlled portion of the trial of non-pharmacologic autonomic interventions.*a

    a. Excluded interventions include vagal nerve stimulation, autonomic neuromodulation, acupuncture, or additional sympathetic or autonomic blocks that could increase procedural risk or confound safety assessment.

  17. Known active acute hepatitis or a history of chronic liver disease (known Child-Pugh Class B or C) or known severe chronic kidney disease or kidney failure (eGFR < 30 ml/min/1.73 m2).

  18. Has known active HBV infection, active HCV infection, or uncontrolled HIV (i.e., not on antiretroviral therapy (ART) or on ART but has detectable viral load).

  19. Has recent active malignancy (received chemotherapy or radiotherapy in the 12 months prior to informed randomization) or active malignancy at informed randomization.*a

    a. Individuals with non-melanoma skin carcinoma (basal or squamous cell skin cancer), or low-grade cervical squamous intraepithelial lesions, which are considered cured and not requiring ongoing therapy, may be enrolled at the discretion of the investigator.

  20. Diagnosed in the 3 months prior to randomization with a new medical condition,*a other than Long COVID, causing new or worsening fatigue that is unresolved at time of randomization.

    a. Medical conditions that could cause new or worsening fatigue include but are not limited to iron deficiency with or without anemia, hypothyroidism, infectious mononucleosis (Epstein-Barr Virus or cytomegalovirus infection), celiac disease, type 1 diabetes mellitus, adrenal insufficiency, cardiac disease (e.g., myocarditis, arrythmia, or cardiomyopathy), metabolic disease, renal disease, or a primary sleep disorder (e.g., obstructive sleep apnea, restless legs syndrome, narcolepsy, or parasomnia).

  21. Participants with known or suspected glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, based on medical record review and judgment of site investigator.

  22. Participants with known history of hypersensitivity to study compounds lidocaine and bupivacaine (or other components of these compounds) or local anesthetics of the amide type.

  23. Participants with clinically significant cardiac conduction disease.*a,b

    1. Including but not limited to Stokes-Adams syndrome; Wolff-Parkinson-White syndrome; severe degrees of sinoatrial, atrioventricular, or intraventricular block in the absence of an artificial pacemaker; sick sinus syndrome; second- or third-degree atrioventricular block, or other conduction abnormalities that, in the investigator's judgment, increase procedural risk or interfere with interpretation of cardiovascular study outcomes.
    2. Presence of an implanted pacemaker, implantable cardioverter-defibrillator, cardiac resynchronization device, or other implanted cardiac rhythm-management device.
  24. Clinically significant ECG findings*a at baseline that may increase procedural risk.

    a. Including but not limited to: corrected QT interval (QTc) >480 milliseconds (ms); newly identified atrial fibrillation or flutter, sustained supraventricular tachycardia, or ventricular arrhythmia; second-degree Mobitz II or third-degree atrioventricular block; ventricular pre-excitation, including Wolff-Parkinson-White pattern; Brugada pattern or another finding associated with clinically important ventricular arrhythmia; evidence of acute myocardial ischemia; or any other ECG abnormality considered clinically significant by the investigator or proceduralist.

  25. Any other Long COVID symptoms besides the primary symptoms of interest that, in the judgment of a site investigator, present as their primary/predominant symptom.

  26. Physical conditions*a that obscure relevant sonoanatomy, alter the anticipated needle trajectory, or otherwise increase the risk of SGB.*b

    1. These include anatomic abnormality, prior surgery, radiation therapy, mass, infection, or other condition involving the neck.
    2. In the judgment of the Study PI or Proceduralist.
  27. Any other circumstance, including medical conditions,*a,b medication use, or other factors that pose a safety risk*c for or interfere with the reliable assessment of trial endpoints.*d

    1. Medical conditions include but are not limited to uncontrolled or clinically unstable cardiovascular disease, including symptomatic arrhythmia, decompensated heart failure, unstable angina, hypertensive emergency or urgency, clinically significant hypotension, or another cardiovascular condition that, in the proceduralist's judgment, increases procedural risk, and active unstable or progressive major neurologic conditions.
    2. Of note, an abnormal vital sign alone is not exclusionary at baseline. However, the abnormal vital sign may be indicative of an updated exclusionary medical condition as described above.
    3. In the site investigator's or proceduralist's judgment.
  28. Inability to safely cooperate with the procedure and required monitoring, including inability to remain appropriately positioned or communicate new symptoms during and after SGB/Sham Study Procedure(s).

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Yksittäinen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Active Comparator: Arm 1- SGB Participants

Participants will receive paired bilateral SGB administered under ultrasound guidance at the anatomical target of cervical vertebrae C6-C7. A skin wheal of approximately 0.5-3 mL buffered plain 1% lidocaine hydrochloride injection will be placed at the needle entry site. A 21- to 30-gauge block needle will be inserted and advanced to the tissue

plane containing the cervical sympathetic chain under real-time ultrasound guidance to deliver 10 mL of preservative-free plain 0.5% bupivacaine hydrochloride injection. N = 136

Bupivacaine hydrochloride injection (without epinephrine) is a long-acting amide-type local anesthetic commonly used for the production of local or regional anesthesia and analgesia in a variety of clinical settings, including surgical, obstetrical, and diagnostic procedures. It is typically administered via local infiltration, peripheral nerve block, or epidural or spinal routes in sterile isotonic solution formulations.

Lidocaine is a local anesthetic of the amide group. Intradermal lidocaine hydrochloride injection is a local anesthetic administered into the superficial layers of the skin. It is commonly used prior to minor procedures including the formation of an intradermal skin wheal. When administered intradermally, lidocaine hydrochloride produces localized numbness without affecting consciousness.

Huijausvertailija: Arm 2- Sham Participants

Participants will receive bilateral sham injections

administered on the same schedule as the active arm. A skin wheal of 0.5-3 mL buffered plain 1% lidocaine hydrochloride will be placed at the needle entry site. To simulate the active SGB procedure, a 21- to 30-gauge needle will be inserted only subcutaneously and with no injected medication. N = 136

Lidocaine is a local anesthetic of the amide group. Intradermal lidocaine hydrochloride injection is a local anesthetic administered into the superficial layers of the skin. It is commonly used prior to minor procedures including the formation of an intradermal skin wheal. When administered intradermally, lidocaine hydrochloride produces localized numbness without affecting consciousness.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Aikaikkuna
Change in the Patient-Reported Outcomes Measurement Information System (PROMIS) 29+2 Preference (PROPr) score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change from baseline in orthostatic intolerance symptoms
Aikaikkuna: Through 8 weeks after randomization

Change in the following measures, all scored as worsened, no change, or improved from baseline:

Sustained increased heart rate (HR) (>= 30 beats per minute (bpm) for 20+ year old or >= 40 bpm for < 20 year old) from supine HR or an absolute HR >= 120 bpm during the first 10 minutes of standing of the Active Stand Test

Sustained decreased blood pressure (BP) (>=20 mmHg in systolic pressure or >=10 mmHg in diastolic pressure) during the first 10 minutes of standing of the Active Stand Test

Any documented orthostatic intolerance (OI) symptoms (dizziness, blurry vision, fatigue, headache, and body pain) documented during the first 10 minutes of standing of the Active Stand Test

Through 8 weeks after randomization
Change in Digit-Span WAIS-IV total age-corrected scaled score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization
Change in Functional Capacity Questionnaire (FUNCAP27) total mean score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization
Change in Hopkins Verbal Learning Test-Revised (HVLT-R) total recall T-score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization
Change in HVLT-R retention % T-score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization
Change in Symbol Digit Modalities Test (SDMT) total T-score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization
Change in the Fatigue Severity Scale (FSS) mean item total score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization
Change in the HVLT-R recognition discrimination index T-score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization
Change in the Orthostatic Intolerance Questionnaire (OIQ) composite total score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization
Change in the total phonemic verbal fluency normed score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization
Change in the total semantic fluency normed score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization
Change in Trail Making Test (TMT) Part A total scaled score and Part B total scaled score
Aikaikkuna: Through 8 weeks after randomization
Through 8 weeks after randomization
Incidence of New Onset Chronic Medical Conditions (NOCMCs)
Aikaikkuna: Through 26 weeks after randomization
Through 26 weeks after randomization
Incidence of Solicited Adverse Events
Aikaikkuna: Through 4 days after SGB or Sham
Through 4 days after SGB or Sham
Incidence of treatment-emergent Medically Attended Adverse Events (MAAEs)
Aikaikkuna: Through 26 weeks after randomization
Through 26 weeks after randomization
Incidence of treatment-emergent serious adverse events (SAEs)
Aikaikkuna: Through 26 weeks after randomization
Through 26 weeks after randomization
Incidence of treatment-emergent unsolicited Adverse Events
Aikaikkuna: Through 12 weeks after randomization
Through 12 weeks after randomization

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Opintojen puheenjohtaja: Anna Bombardieri, MD PhD MSc, Stanford University

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Keskiviikko 9. joulukuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 9. huhtikuuta 2029

Opintojen valmistuminen (Arvioitu)

Maanantai 9. huhtikuuta 2029

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 13. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Torstai 19. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 19. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Viimeksi vahvistettu

Torstai 5. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • 26-0004
  • 1OT2HL156812 (Yhdysvaltain NIH-apuraha/sopimus)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Yhdysvalloissa valmistettu ja sieltä viety tuote

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .